Effects Of Ticagrelor 60mg Prolonging Dual-antibody Therapy On Postoperative Bleeding Risk-clinical Benefits In ACS Patients After PCI

Objective:To explore the effects of ticagrelor 60 mg prolonging dual-antibody therapy on postoperative bleeding risk-clinical benefits in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods:During the period from October 2018 to September 2019,204 ACS patients who underwent PCI and drug eluting stent implantation in East Hunan Hospital Affiliated to Hunan Normal University were enrolled.After treated with daily routine dual anti-platelet therapy(DAPT)[ticagrelor(90mg bid)、 aspirin(100mg qd)] for 12 months,they were divided into control group and study group,102 cases in each group.The study group was continuously treated with daily prolonged DAPT[ticagrelor(60mg bid)、 aspirin(100mg qd)],while control group was treated with [placebo(60mg bid)、 aspirin(100mg qd)].The patients were followed up by telephone 、We Chat and outpatient service for 12 months.The occurrence of major adverse cardiovascular events(MACE)and adverse reactions(bleeding,dyspnea)during the treatment follow-up was recorded.Result:1.The incidence of MACE in study group was significantly lower than that in control group(P<0.05);2.The incidence rate of bleeding,dyspnea and total adverse reactions in both group were low,without significant difference between the two groups(P>0.05).Conclusion:Ticagrelor 60 mg with aspirin prolonging dual-antibody therapy can more reduce occurrence of cardiovascular complications in ACS patients after PCI,without increasing bleeding risk.